within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AA19_Eflapegrastim;
model Eflapegrastim 
   extends Pharmacolibrary.Drugs.ATC.L.L03AA19;

  annotation(Documentation(
    info ="<html><body><p>Eflapegrastim is a long-acting, recombinant human granulocyte colony-stimulating factor (G-CSF) analog, conjugated to a human IgG4 Fc fragment via a polyethylene glycol linker. It is used for the reduction in the duration of severe neutropenia in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. It is approved for use in the United States.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult cancer patients; healthy volunteers and patients with breast cancer following subcutaneous administration.</p><h4>References</h4><ol><li><p>Jeon, Y, et al., &amp; Lee, H (2022). A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Subcutaneous Eflapegrastim in Healthy Japanese and Caucasian Subjects. <i>Drugs in R&amp;D</i> 22(1) 71–87. DOI:<a href=&quot;https://doi.org/10.1007/s40268-021-00379-8&quot;>10.1007/s40268-021-00379-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34993933/&quot;>https://pubmed.ncbi.nlm.nih.gov/34993933</a></p></li><li><p>Shin, KH, et al., &amp; Yu, KS (2013). Pharmacokinetic and pharmacodynamic properties of a new long-acting granulocyte colony-stimulating factor (HM10460A) in healthy volunteers. <i>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</i> 27(2) 149–158. DOI:<a href=&quot;https://doi.org/10.1007/s40259-013-0010-0&quot;>10.1007/s40259-013-0010-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23359067/&quot;>https://pubmed.ncbi.nlm.nih.gov/23359067</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Eflapegrastim;
